The block deal data on BSE showed that JP Morgan Funds bought over 11.23 lakh shares of TCS at an average price of Rs 2,199 apiece, and the total deal value stood at Rs 246.98 crore.
In June, less than one-third (33 per cent) of the total traded quantity at the bourses was converted into delivery
Market players said the stock is easily prone to manipulation as hardly any shares are with the public
The bank posted a net profit of Rs 506.5 crore in Q4FY20 compared to net loss of Rs 991.3 crore in Q4FY19.
In separate circulars, the exchanges said futures and options (F&O) contracts will not be available for trading in the securities of these three companies with effect from August 28, 2020
The company has worked out the floor price of an equity share of Rs 33.82 to buy 96.53 crore scrips with the public for about Rs 3,264 crore
Reliance Industries on Friday became the first Indian company to cross the Rs 11 trillion market valuation mark
Its net profit fell sharply, by 40 per cent, to Rs 421.43 crore from Rs 693.58 crore in Q4FY19.
The company logged a profit ofRs 142.50 crore in January-March period a year ago, Century Textiles and Industries Ltd (CTIL) said in a BSE filing.
Lower demand for crude oil and petroleum products had impacted the prices and refining margins of the company
Reliance Industries Ltd's Rs 53,124 crore rights issue, which has already been oversubscribed, on Tuesday received further bids for 8.8 crore
The clarification to the BSE by Vodafone Idea comes a day after reports that Alphabet Inc's Google is eyeing about 5% stake in the telecom company.
Units worth nearly Rs 150 crore changed hands on the NSE and another Rs 554 crore on the BSE.
The company had posted a net profit of Rs 635.88 crore in the same period previous fiscal, Sun Pharma said in a BSE filing
At close of trade, the company's market capitalisation stood at Rs 1,58,902.37 crore on the BSE.
The fee rebate has been declared following Finance Minister Nirmala Sitharaman's several announcements to rescue the ailing MSME sector
The company had posted a net profit of Rs 146.81 crore for the same period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.
Analysts say acquirer may have found the firm attractive at the valuation at which it was available at
The net profit for the period declined 42.2 per cent to Rs 123 crore on YoY basis, according to a BSE filing by the company
Profit down due to Covid provisioning and lower other income